Predicting complicated Crohn's disease and surgery: Phenotypes, genetics, serology and psychological characteristics of a population-based cohort

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 3, 2013, Pages 274-283

  Ryan, J D ^a   Silverberg, M S ^b   Xu, W ^b   Graff, L A ^a   Targownik, L E ^a   Walker, J R ^a   Carr, R ^a   Clara, I ^a   Miller, N ^a   Rogala, L ^a   Bernstein, C N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIBODY; IMMUNOGLOBULIN G; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; FOLLOW UP; GENE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IL23R GENE; ILEUM DISEASE; INTESTINE STENOSIS; INTESTINE SURGERY; MALE; NEUROSIS; NOD2 GENE; OUTCOME ASSESSMENT; PHYSICAL ABUSE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; SEMI STRUCTURED INTERVIEW; SEROLOGY; SEXUAL ABUSE; VALIDATION STUDY;

ADAPTATION, PHYSIOLOGICAL; ADULT; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CARRIER PROTEINS; COHORT STUDIES; CROHN DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN; RISK FACTORS; SACCHAROMYCES CEREVISIAE;

EID: 84879780190     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12368     Document Type: Article

References (65)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ,. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
2. Silverberg MS, Satsangi J, Ahmad T, et al,. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World congress of gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5-36.
3. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J,. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6.
4. Cosnes J, Cattan S, Blain A, et al,. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
5. Blonski W, Buchner AM, Lichtenstein GR,. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am 2012; 41: 443-62.
6. Savoye G, Salleron J, Gower-Rousseau C, et al,. Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18: 2072-8.
7. Satsangi J, Silverberg MS, Vermeire S, Colombel JF,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
8. Cho JH, Brant SR,. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-12.
9. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP,. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99: 2393-404.
10. Adler J, Rangwalla SC, Dwamena BA, Higgins PD,. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011; 106: 699-712.
11. Li Y, Mao Q, Shen L, et al,. Interleukin-23 receptor genetic polymorphisms and Crohn's disease susceptibility: a meta-analysis. Inflamm Res 2010; 59: 607-14.
12. Hampe J, Franke A, Rosenstiel P, et al,. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-11.
13. Rioux JD, Xavier RJ, Taylor KD, et al,. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604.
14. Roberts RL, Gearry RB, Hollis-Moffatt JE, et al,. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol 2007; 102: 2754-61.
15. Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ,. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS ONE 2008; 3: e3391.
16. Prescott NJ, Fisher SA, Franke A, et al,. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 2007; 132: 1665-71.
17. Weersma RK, Stokkers PC, van Bodegraven AA, et al,.; Dutch Initiative on Crohn and Colitis (ICC). Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009; 58: 388-95.
18. Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C,. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 2010; 139: 1630-41.
19. Graff LA, Walker JR, Bernstein CN,. Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management. Inflamm Bowel Dis 2009; 15: 1105-18.
20. Singh S, Graff LA, Bernstein CN,. Do NSAIDs, antibiotics, infections or stress trigger flares in IBD? Am J Gastroenterol 2009; 104: 1298-313.
21. Bonaz B, Bernstein CN,. Brain-gut interactions in inflammatory bowel diseases. Gastroenterology 2013; 144: 36-49.
22. Chartier M, Walker JR, Naimark B,. Health risk behaviors and mental health problems as mediators of the relationship between childhood abuse and adult health. Am J Public Health 2009; 99: 847-54.
23. Wegman HL, Stetler C,. A meta-analytic review of the effects of childhoodabuse on medical outcomes in adulthood. Psychosom Med 2009; 71: 805-12.
24. Felitti V, Anda R,. The relationship of adverse childhood experiences to adult medical disease, psychiatric disorders, and sexual behavior: implications for health care. In:, Lanius R, Vermetten E, Pain C, eds. The impact of early life trauma on health and disease. Cambridge: Cambridge University Press, 2010; 77-87.
25. Briere J, Elliot DM,. Prevalence and psychological sequence of self-reported childhood physical and sexual abuse in general population. Child Abuse Negl 2003; 27: 1205-22.
26. Raison CL, Miller AH,. When not enough is too much. The role of insufficient glucocorticoid signalling in the pathophysiology of stress-related disorders. Am J Psychiatr 2003; 160: 1554-65.
27. Heim C, Newport DJ, Heit S, et al,. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000; 284: 592-7.
28. Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB,. Pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatr 2001; 158: 575-81.
29. Danese A, Pariante CM, Caspi A, et al,. Childhood maltreatment predicts adult inflammation in a life-course study. PNAS 2007; 104: 1319-24.
30. Segerstrom SC, Miller GE,. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull 2007; 130: 601-30.
31. Bernstein CN, Blanchard JF, Rawsthorne P, et al,. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149: 916-24.
32. Graff LA, Walker JR, Lix L, et al,. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006; 4: 1491-501.
33. Lix LM, Graff LA, Walker JR, et al,. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1575-84.
34. Walker JR, Ediger JP, Graff LA, et al,. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008; 103: 1989-97.
35. Longobardi T, Walker JR, Graff LA, et al,. Health service utilization in IBD: comparison of self-report and administrative data. BMC Health Serv Res 2011; 11: 137.
36. McCrae RR, Martin TA, Costa PT Jr,. Age trends and age norms for the NEO Personality Inventory-3 in adolescents and adults. Assessment 2005; 12: 363-73.
37. World Health Organization. Composite International Diagnostic Interview. Version 2.1. Geneva: World Health Organization, 1997.
38. Wittchen HU,. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994; 28: 57-84.
39. Horne R, Weinman J,. Patient's beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-67.
40. Ediger JP, Walker JR, Graff L, et al,. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1417-26.
41. Okazaki T, Wang MH, Rawsthorne P, et al,. Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis 2008; 14: 1528-41.
42. Devlin SM, Yang H, Ippoliti A, et al,. NOD2 variants and antibody response to microbial antigens in Crohn's disease subjects and their unaffected relatives. Gastroenterology 2007; 132: 576-86.
43. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr,. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139: 1147-55.
44. Solberg IC, Vatn MH, Høie O, et al,.; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
45. Tarrant KM, Barclay ML, Frampton CM, Gearry RB,. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93.
46. Dhillon SL, Loftus EV Jr, Tremaine WJ, et al,. The natural history of surgery for Crohns disease in a population-based cohort from Olmsted County, Minnesota (Abstract 825). Am J Gastroenterol 2005; 100 (Suppl.): S305.
47. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
48. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB,. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
49. Lakatos L, Kiss LS, David G, et al,. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011; 17: 2558-65.
50. Brant SR, Wang MH, Rawsthorne P, et al,. A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol 2007; 102: 313-23.
51. Kaila B, Orr K, Bernstein CN,. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol 2005; 19: 717-21.
52. Mow WS, Vasiliauskas EA, Lin YC, et al,. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-24.
53. Arnott ID, Landers CJ, Nimmo EJ, et al,. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99: 2376-84.
54. Papadakis KA, Yang H, Ippoliti A, et al,. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13: 524-30.
55. Wolters FL, Russel MG, Sijbrandij J, et al,.; European Collaborative Study Group On Inflammatory Bowel Disease. Disease outcome of inflammatory bowel disease subjects: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 2006; 243: 46-54.
56. Prideaux L, De Cruz P, Ng SC, Kamm MA,. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012; 18: 1340-55.
57. Rieder F, Schleder S, Wolf A, et al,. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010; 16: 1367-75.
58. Dubinsky MC, Kugathasan S, Mei L, et al,.; Western Regional Pediatric IBD Research Alliance; Pediatric IBD Collaborative Research Group; Wisconsin Pediatric IBD Alliance. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6: 1105-11.
59. Lichtenstein GR, Targan SR, Dubinsky MC, et al,. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011; 17: 2488-96.
60. Lesage S, Zouali H, Cézard JP, et al,.; EPWG-IBD Group; EPIMAD Group; GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 subjects with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-57.
61. Franke A, McGovern DP, Barrett JC, et al,. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-25.
62. Gearry RB, Roberts RL, Burt MJ, et al,. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm Bowel Dis 2007; 13: 1220-7.
63. Lakatos PL, Szamosi T, Lakatos L,. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007; 13: 6134-9.
64. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
65. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M,. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002.